Experimental vaccine shows promise against invasive fungi

Researchers at the CBMA have published a pre-clinical study exploring a novel liposomal vaccine candidate targeting Candida albicans, a major cause of invasive fungal infections in immunocompromised patients.

The study, published in NPJ Vaccines, demonstrated improved survival in a mouse model and highlights the potential of antigen-loaded liposomes to induce protective immune responses. This research aligns with the World Health Organization’s global priorities for addressing emerging fungal threats, particularly in the context of rising antifungal resistance and environmental change.

By focusing on fundamental biological mechanisms with potential translational value, CBMA contributes to the broader scientific understanding of infectious disease control in a changing world.